Skip to main content
SpringerLink
Log in

Treatment with cyclosporin of patients with idiopathic nephrotic syndrome

  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Conclusions

The prognosis of idiopathic nephrotic syndrome was transformed with the use of corticosteroids and immunosuppressive drugs. The high percentage of initial remission in minimal change lipoid nephrosis should not obscure the frequency of development to corticodependence or of multiple relapses which lead to the complications of protracted corticosteroid therapy. Focal-segmental glomerulonephritis and membranous glomerulopathy often evolve to relentless chronic renal failure. The use of immunosuppressive therapy has reduced the percentage of unfavourable evolution, but these cytotoxic agents are not devoid of short-term side effects and entail some long-term risk of malignancy [6, 26, 27]. The prognosis in cases which resist any form of treatment is distinctly unfavourable. As for the earlier forms of therapy, the use of cyclosporin in treating idiopathic nephrosis is empirical: the mechanism of immunosuppression with CyA is a continuing puzzle and the physiopathology of nephrosis is poorly understood. Moreover, cyclosporin, in contrast with conventional treatments, entails a definite risk of renal toxicity. Despite these drawbacks, preliminary results showed that approximately two-thirds of patients with idiopathic nephrotic syndrome resistant to other therapy clearly benefited from cyclosporin treatment, whereas only 7% suffered severe side effects. These results justify studies of cyclosporin treatment on a larger scale. The goal of these studies should be threefold: first, to delineate more precisely the indications and contra-indications of cyclosporin in glomerular diseases, to avoid anarchic prescription of this powerful but expensive and potentially dangerous drug; second, to determine the percentage of patients who will become dependent on long-term cyclosporin; and third, to specify the risk of nephrotoxicity in case of such protracted treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abb J, Abb H (1983) Effect of cyclosporin on human leukocyte interferon production: selective inhibition of IFN-gamma synthesis. Transplant Proc 15: 2380

    Google Scholar 

  2. Adhikari M (1985) Ciclosporin (CyA) in steroid-insensitive nephrotic syndrome in Durban, South Africa. In: Schindler R (ed) Ciclosporin in autoimmune diseases, vol 1. Springer, Berlin, p 323

    Google Scholar 

  3. Balcke P, Derfler K, Kopsa H, Schein W, Bailer H, Sunder-Plassmann G, Zazgomik J (1987). Cyclosporintherapie bei Minimal-Change-Nephritis. Wien Med Wochenschr [Suppl 101] 137: XV [abstr]

    Google Scholar 

  4. Beaufils H, Alphonse JC, Guedon J, Legrain M (1978) Focal glomerulosclerosis: natural history and treatment. A report of 70 cases. Nephron 21: 75

    Google Scholar 

  5. Bender WL, Whelton A, Boeschorner WE, Darwish MO, Hall-Craggs M, Solez K (1984) Interstitial nephritis, proteinuria and renal failure caused by non-steroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. Am J Med 76: 1006

    Google Scholar 

  6. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta V, Wasserman LR (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304: 441

    Google Scholar 

  7. Borel JF, Ryffel B (1985) The mechanism of action of ciclosporin. A continuing puzzle. In: Ciclosporin in autoimmune disease, vol 1. Schindler R (ed) Springer-Verlag, Berlin, p 24

    Google Scholar 

  8. Boulton-Jones JM, McWilliams G, Chandrachud L (1986) Variation in charge on red cells of patients with different glomerulopathies. Lancet II: 186

    Google Scholar 

  9. Brandis M. Burghard R, Leititis J, Zimmerhackl B, Hildebrandt F, Helmchen U (1987) Cyclosporin A for treatment in nephrotic syndromes. Pediatr Nephrol 1: C42 [abstr F17-4]

  10. Brenner BM, Hostetter Th, Humes HD (1978) Molecular basis of proteinuria of glomerular origin. N Engl J Med 298: 826

    Google Scholar 

  11. Brodehl J (1985) Cyclosporin A bei glomerulären Erkrankungen. Internist (Berlin) 26: 578

    Google Scholar 

  12. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG (1978) The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10: 213

    Google Scholar 

  13. Capodicasa G, De Santo NG, Nuzzi F, Giordano C (1986) Cyclosporin A in nephrotic syndrome of childhood. A 14-month experience. Int J Pediatr Nephrol 7: 69

    Google Scholar 

  14. Cattran DC, Dossetor J, Keown P, Stiller C, Halloran P, Clark WF (1986) Cyclosporin treatment of patients with glomerulonephritis. Kidney Int 29: 182 [abstr]

    Google Scholar 

  15. Chasis H, Goldring W, Baldwin DS (1950) The effect of nitrogen mustard on renal manifestations of human glomerulonephritis. J Clin Invest 29: 804

    Google Scholar 

  16. Clasen W, Kindler J, Sieberth HG (1985) Behandlung der Minimal-Changes-Nephritis mit Cyclosporin A. Nieren- und Hochdruckkr 14: 381 [abstr]

    Google Scholar 

  17. Couser WG, Salant DJ (1980) In situ immune complex formation and glomerular injury. Kidney int 17: 1

    Google Scholar 

  18. De Santo NG, Capodicasa G, Giordano C (1987) Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am J Nephrol 7: 74

    Google Scholar 

  19. Eyres KE, Mallick NP, Taylor G (1976) Evidence for cell mediated immunity to renal antigens in minimal change nephrotic syndrome. Lancet i: 1158

    Google Scholar 

  20. Farnsworth EB (1950) Metabolic changes associated with the administration of adrenocorticotrophin in the nephrotic syndrome. Proc Soc Exp Biol Med 74: 60

    Google Scholar 

  21. Glassock RJ, Adler SG, Ward HJ, Cohen AH (1986) Primary glomerular diseases. In: Brenner BM, Rector FC (eds) The Kidney, vol 1, 3rd ed. WB Saunders, Philadelphia, p 929

    Google Scholar 

  22. Habib R, Churg J, Bernstein J, Cameron JS, Cohen Ah, Gagnadoux MF, Lewis EJ (1984) Minimal change disease, mesangial proliferative glomerulonephritis and focal sclerosis: individual entities or a spectrum of disease? In: Robinson RR (ed) Nephrology (Proceedings of the 9th congress of nephrology), vol 1. Springer-Verlag, Berlin, p 634

    Google Scholar 

  23. Hoyer PF, Krull F, Brodehl J (1986) Cyclosporin in frequently relapsing minimal change nephrotic syndrome. Lancet II: 335

    Google Scholar 

  24. International Study of Kidney Disease in Children (1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int 20: 765

    PubMed  Google Scholar 

  25. International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98: 561

    PubMed  Google Scholar 

  26. Kahn MF, Arlet J, Bloch-Michel H, Caroit M, Chaouat Y, Renier JC (1979) Leucémies aiguës après traitement par agents cytotoxiques en rhumatologie. 19 observations chez 2006 patients. Nouv Presse Med 8: 1393

    Google Scholar 

  27. Kleinknecht C, Guesry P, Lenoir G, Broyer M (1977) High-cost benefit of chlorambucil in frequently relapsing nephrosis. N Engl J Med 296: 48

    Google Scholar 

  28. Korbet SM, Schwartz MM, Lewis EJ (1986) The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine (Baltimore) 65: 304

    Google Scholar 

  29. Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B (1975) Lymphokines and nephrotic syndrome. Lancet I: 271

    Google Scholar 

  30. Lagrue G, Laurent J, Belghiti D, Robeva R (1986) Cyclosporin and idiopathic nephrotic syndrome. Lancet II: 692

    Google Scholar 

  31. Lagrue G, Laurent J, Robeva R (1986) Membranoproliferative glomerulonephritis associated with Buckley's syndrome, treated with Cyclosporin. Nephron 44: 382

    Google Scholar 

  32. Larsson EL (1980) Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol 124: 2828

    Google Scholar 

  33. Levin M, Smith C, Walther MSD, Gascoine P, Barratt TM (1985) Steroid-responsive nephrotic syndrome; a generalised disorder of membrane negative charge. Lancet II: 239

    Google Scholar 

  34. Ling CY, Hsu HC (1986) Histopathological and immunological studies in spontaneous remission of nephrotic syndrome after intercurrent measles infection. Nephron 42: 110

    Google Scholar 

  35. Luetscher Jr JA, Deming QB, Harvey J, Lew W, Poo LJ (1950) Treatment of nephrosis with cortisone. J Clin Invest 29: 1576

    Google Scholar 

  36. Mallick NP (1977) The pathogenesis of minimal change nephropathy. Clin Nephrol 7: 87

    Google Scholar 

  37. Meyrier A, Simon P (1987) Traitement des syndromes néphrotiques corticorésistants de l'adulte. Lésions glomérulaires minimes et hyalinose segmentaire et focale. In: Actualités Néphrologiques de l'hôpital Necker. Flammarion, Paris, p 121

    Google Scholar 

  38. Meyrier A, Simon P, Perret G, Condamin-Meyrier MC (1985) Use of ciclosporin in idiopathic corticoresistant or corticodependent nephrotic syndrome (minimal change glomerulopathy and focal-segmental hyalinosis). In: Schindler R (ed) Cyclosporin in autoimmune diseases, vol 1. Springer, Berlin, Heidelberg, New York, Tokyo, p 316

    Google Scholar 

  39. Meyrier A, Simon P, Perret G, Condamin-Meyrier MC (1986) Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A. Br Med J 292: 789

    Google Scholar 

  40. Meyrier A, Simon P, Perret G, Condamin MC (1986) Cyclosporin in lipoid nephrosis and focalsegmental hyalinosis resistant to other treatments. Kidney Int 29: 197 [abstr]

    Google Scholar 

  41. Niaudet P, Habib R, Gagnadoux MF, Tete MJ, Broyer M (1987) Traitement des néphroses graves chez l'enfant. In: Actualités Néphrologiques de l'hôpital Necker. Flammarion, Paris, p 141

    Google Scholar 

  42. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG (1986) Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 29: 1215

    Google Scholar 

  43. Ooi BS, Orlina AR, Masmiti L (1974) Lymphocytotoxins in primary renal disease. Lancet ii: 1348

    Google Scholar 

  44. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Imbasciati E (1987) Treatment of idiopathic membranous nephropathy. In: Grunfeld JP, Bach JF, Crosnier J, Funck-Brentano JL, Maxwell MH (eds) Advance in nephrology. Year Book, Chicago, pp 191–218

    Google Scholar 

  45. Rao TKS, Friedman EA (1987) Prospective trial of cyclosporine in refractory nephrotic syndrome in adults: preliminary findings. Kidney Int 31: 214 [abstr]

    Google Scholar 

  46. Saint Hillier Y, Morel-Maroger L, Woodrow D, Richet G (1975) Focal and segmental hyalinosis. In: Hamburger J, Crosnier J, Maxwell MH (eds) Advance in Nephrology. Year Book, Chicago, pp 67–88

    Google Scholar 

  47. Schnaper HW, Aune TM (1985) Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children. J Clin Invest 76: 341

    Google Scholar 

  48. Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet ii: 556

    Google Scholar 

  49. Tejani A (1987) Cyclosporin treatment in patients with primary glomerular diseases. Int J Pediatr Nephrol 8: 1

    Google Scholar 

  50. Tejani A, Butt K, Khawar R, Suthanthiran M, Rosenthal CJ, Trachtman H, Fusi M (1986) Cyclosporin-induced remission of relapsing nephrotic syndrome in children. Kidney Int 29: 206 [abstr]

    Google Scholar 

  51. Turney JH, Adu D, Michael J, MCMaster P (1986) Recurrent crescentic glomerulonephritis in renal transplant recipient treated with cyclosporin. Lancet i: 1104

    Google Scholar 

  52. Velosa JA, Holley KE, Torres VE, Offord KP (1983) Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 58: 568

    Google Scholar 

  53. Verani RR, Hawkins EP (1986) Recurrent focal segmental glomerulosclerosis. A pathological study of the early lesion. Am J Nephrol 6: 263

    Google Scholar 

  54. Waldo FB, Kohaut EC (1987) Therapy of focal segmental glomerulosclerosis with cyclosporin A. Pediatr Nephrol 1: 180

    Google Scholar 

  55. Zimmerman SW (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22: 32

    Google Scholar 

  56. Zucchelli P, Cagnoli L, Casanova S (1983) Minimal change glomerulopathy in humans. In: Bertani T, Remuzzi G (ed) Glomerular injury 300 years after Morgagni. Wichtig, Milano, p 179

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology and Dialysis Unit, Hôpital Avicenne, 125 route de Stalingrad, F-93009, Bobigny, France

    Alain Meyrier

Authors
  1. Alain Meyrier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyrier, A. Treatment with cyclosporin of patients with idiopathic nephrotic syndrome. Springer Semin Immunopathol 9, 441–450 (1987). https://doi.org/10.1007/BF00197220

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00197220

Keywords

Search

Navigation